Clinical trial · Observational
Neoadjuvant Radiotherapy Before Surgery for Rectal Cancer, Surgical and Oncological Outcome Analysis, Retrospective Case Control Study in a Single Institute.
NCT06713824CI-TRIAL-00083210active not recruitingClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Pre-operative radiotherapy for clinical stage 3 rectal cancer outcome analysis, retrospective case-control study.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| General Surgery | — | UNRESOLVED | — |
| Radiology | — | UNRESOLVED | — |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (1)
- label
- neo-adjuvant radiotherapy and surgery
- description
- receive radiation therapy before surgery
Primary outcomes (2)
- measure
- Recurrence rate
- timeFrame
- 5-year postoperative period
- description
- The disease recurrence rate refers to the likelihood of a disease reappearing after initial treatment, encompassing both local recurrence and distant metastasis. Local recurrence is defined by medical standards as the reappearance of a tumor at the original site or nearby lymph nodes, typically confirmed through imaging or pathological examination and commonly occurring within 1-3 years post-surgery. Distant metastasis, on the other hand, is identified when tumor cells spread to distant organs, such as the liver, lungs, or bones, and is confirmed through imaging modalities (e.g., CT, MRI, or PET scans) or biopsy. The incidence of distant metastasis is closely related to tumor staging, such as the TNM classification.
- measure
- survival rate
- timeFrame
- 5-year postoperative period
- description
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 20 Years
Show eligibility criteria text
Inclusion Criteria: * Rectal cancer, clinical stage T3 or higher, with no distant metastasis. * Age \> =20 years, ASA class I-III. * Underwent surgery. * Complete medical records. Exclusion Criteria: * Non-rectal cancer. * Clinical stage T1-T2. * Stage IV with distant metastasis. * Age \< 20 years, ASA class IV-V. * Incomplete medical records. * HIV-positive patients (Human Immunodeficiency Virus). * Patients who completed treatment after October 1, 2024.
References
Publications (0)
Data not yet available
No reference posted for this study.